Robert Battat MD (@battatmd4ibd) 's Twitter Profile
Robert Battat MD

@battatmd4ibd

Physician-scientist. Director of Center for Clinical Excellence and Translational Research in #IBD @chumontreal @crchum. Tweets ≠ endorsement/advice. 🇨🇦

ID: 1263477710845874179

linkhttps://scholar.google.com/citations?user=P83EIHMAAAAJ&hl=en calendar_today21-05-2020 14:32:29

1,1K Tweet

999 Followers

420 Following

Jean-Frederic Colombel (@jeanfredericco1) 's Twitter Profile Photo

A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogeni… pubmed.ncbi.nlm.nih.gov/39080486/ Progressing towards finding cause and prevention 👍

NBA on ESPN (@espnnba) 's Twitter Profile Photo

"They play a game that matches the way Team USA plays." @windhorstespn on Canada's men's national basketball team potentially being an issue 🤔

Ben Click (@benclickmd) 's Twitter Profile Photo

Ever wonder if you should biopsy normal neoTI after resection in CD? ▶️Normal (i0) endoscopy ▶️Active inflammation ⬆️POR risk More evidence that active 🔬 disease can risk stratify IBD clinical risk. Ravi Shah Benjamin Cohen MD MAS Jordan Axelrad, MD, MPH Edward Barnes MD MPH journals.lww.com/ajg/abstract/9…

Shubha Bhat, PharmD (@gi_pharmd) 's Twitter Profile Photo

Robert Battat MD Peter Higgins Uma Mahadevan Ben Click Valid points Robert Battat MD. We will also potentially have another IL-23 inhibitor (guselkumab) FDA approved in Fall 2024. Would have been great to see Stelara price reduction with Medicare happen much earlier.

Robert Battat MD (@battatmd4ibd) 's Twitter Profile Photo

Article in The New York Times on drug price reductions. Why do #crohns disease and ulcerative colitis remain hidden? Stelara listed for “autoimmune conditions”. Jardiance listed as drug for specific disease, not “metabolic/heart/kidney conditions” Peter Loftus Uma Mahadevan #IBDSuperHeroes

Article in <a href="/nytimes/">The New York Times</a> on drug price reductions. Why do #crohns disease and ulcerative colitis remain hidden? Stelara listed for “autoimmune conditions”. Jardiance listed as drug for specific disease, not “metabolic/heart/kidney conditions” <a href="/Loftus/">Peter Loftus</a> <a href="/UmaMahadevanIBD/">Uma Mahadevan</a> <a href="/IBDSuperHeroes/">#IBDSuperHeroes</a>
IBDJournal & CC360 (@ibdjournals) 's Twitter Profile Photo

Largest population based study to examine the effects of cannabis in IBD 🌿 ⬆️ ED visits ⬆️ Hospitalizations ⬆️ Use of steroids and opioids 💊 🚫 IBD related surgery or mortality Penn State Division of GI and Hepatology academic.oup.com/ibdjournal/art…

Maria T. Abreu (@ibddocmaria) 's Twitter Profile Photo

Congress' idea to consolidate NIH institutes like NIDDK is bad for GI! This will set back research and make it harder to discover treatments for our patients. 😡 Join me + @amergastroassn to stop this. #MariasMusings gastro.quorum.us/campaign/66688/

د. محمد عبدالله شهاب (@drmohamadshehab) 's Twitter Profile Photo

How would you rank novel therapies such as etrasimod, risankizumab, mirikizumab, and guselkumab in UC ❓ What treatment 🎯 you are interested in ❓ Our recent NMA at CGH cghjournal.org/article/S1542-… Talat Bessissow Vipul Jairath MBChB DPhil Beatriz Gros #MondayNightIBD Shrinivas Bishu

Esteban FV (@efuentesval) 's Twitter Profile Photo

👩‍⚕️👨‍⚕️Combined Advanced Targeted Therapy in IBD ➡️ Only 2️⃣ RCT so far: IFX/Natalizumab 🆚️IFX ; Gusel/goli 🆚️ gusel 🆚️ goli (VEGA trial). ➡️ Refractory IBD, concurrent EIM, high-risk disease, or concomitant autoimmune disorders ➡️Ongoing phase IIb RCTs: DUET-CD and DUET-UC

👩‍⚕️👨‍⚕️Combined Advanced Targeted Therapy in IBD

➡️ Only 2️⃣ RCT so far: IFX/Natalizumab 🆚️IFX ; Gusel/goli 🆚️
gusel 🆚️ goli (VEGA trial).

➡️ Refractory IBD, concurrent EIM, high-risk disease, or concomitant autoimmune disorders

➡️Ongoing phase IIb RCTs: DUET-CD and DUET-UC
Antonio Caballero Mateos PhD (@dr_acaballero_) 's Twitter Profile Photo

🗒️2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment 💊 Y-ECCO  #IBD #MedEd #GITwitter #MedTwitter 1️⃣4️⃣ Statements and 6️⃣Practice points 1️⃣ 5-ASA is not recommended🚫for the induction or maintenance therapy in CD➡️consistent lack of evidence. 🧵👇

🗒️2024 ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment 💊

<a href="/Y_ECCO_IBD/">Y-ECCO</a>
 #IBD #MedEd #GITwitter #MedTwitter

1️⃣4️⃣ Statements and 6️⃣Practice points

1️⃣ 5-ASA is not recommended🚫for the induction or maintenance therapy in CD➡️consistent lack of evidence.

🧵👇
Sun-Ho Lee MD PhD (@sunholee15) 's Twitter Profile Photo

👉Top contributing factors for future risk of CD in the GEM-integrative risk score ⬆️Increased risk of CD: FCP⬆️LMR (gut permeability)⬆️ g_Ruminococcus torques⬆️fucose degradation pathway⬆️ ⬇️Decreased risk of CD: queuosine biosynthesis pathway⬇️ g_lachnospira⬇️ (3/7)

👉Top contributing factors for future risk of CD in the GEM-integrative risk score

⬆️Increased risk of CD: 
FCP⬆️LMR (gut permeability)⬆️ g_Ruminococcus torques⬆️fucose degradation pathway⬆️

⬇️Decreased risk of CD: 
queuosine biosynthesis pathway⬇️ g_lachnospira⬇️

(3/7)